DermTech Management
DMTKDelisted Stock | USD 0.04 0.02 71.36% |
DermTech employs about 206 people. The company is managed by 17 executives with a total tenure of roughly 481 years, averaging almost 28.0 years of service per executive, having 12.12 employees per reported executive. Inspection of DermTech's management performance can provide insight into the company performance.
DermTech |
DermTech Management Team Effectiveness
The company has return on total asset (ROA) of (0.386) % which means that it has lost $0.386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2175) %, meaning that it created substantial loss on money invested by shareholders. DermTech's management efficiency ratios could be used to measure how well DermTech manages its routine affairs as well as how well it operates its assets and liabilities.DermTech Workforce Comparison
DermTech is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,609. DermTech holds roughly 206 in number of employees claiming about 8% of equities under Health Care industry.
DermTech Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DermTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on DermTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, DermTech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sun Kevin M over six months ago Disposition of 445 shares by Sun Kevin M of DermTech at 0.34 subject to Rule 16b-3 | ||
Akhavan Ramin over six months ago Disposition of 1757 shares by Akhavan Ramin of DermTech at 0.31 subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Disposition of 2530 shares by Sun Kevin M of DermTech at 0.31 subject to Rule 16b-3 | ||
Todd Wood over six months ago Acquisition by Todd Wood of 85114 shares of DermTech subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Disposition of 445 shares by Sun Kevin M of DermTech at 0.7 subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Disposition of 2531 shares by Sun Kevin M of DermTech at 0.88 subject to Rule 16b-3 | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 223 shares of DermTech | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 514 shares of DermTech |
DermTech Notable Stakeholders
A DermTech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DermTech often face trade-offs trying to please all of them. DermTech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DermTech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Bret Christensen | CEO President | Profile | |
Kevin MBA | Treasurer CFO | Profile | |
Burkhard MD | Chief Officer | Profile | |
Todd Wood | Chief Officer | Profile | |
Daniel Visage | Senior Access | Profile | |
Steven Stone | Senior Development | Profile | |
Loren MD | Chief Officer | Profile | |
JD Esq | General Counsel | Profile | |
Ray JD | G Counsel | Profile | |
Jennifer Eilemberg | Chief Officer | Profile | |
Ray Bassi | VP Sales | Profile | |
John MD | CEO Pres | Profile | |
William Zondler | Chief Officer | Profile | |
Steve Kunszabo | Director Relations | Profile | |
Michael Howell | Chief Officer | Profile | |
Mark Aguillard | Chief Officer | Profile | |
Claudia Ibarra | Chief Officer | Profile |
About DermTech Management Performance
The success or failure of an entity such as DermTech often depends on how effective the management is. DermTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DermTech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DermTech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. Dermtech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 255 people.
DermTech Workforce Analysis
Traditionally, organizations such as DermTech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DermTech within its industry.DermTech Manpower Efficiency
Return on DermTech Manpower
Revenue Per Employee | 74.3K | |
Revenue Per Executive | 899.8K | |
Net Loss Per Employee | 489.7K | |
Net Loss Per Executive | 5.9M | |
Working Capital Per Employee | 234.5K | |
Working Capital Per Executive | 2.8M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in DermTech Stock
If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |